Skip to search formSkip to main contentSkip to account menu

PI103

Known as: PI 103, PI-103 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

FuransPyridinesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Real-time monitoring of hypertrophy in HL-1 cardiomyocytes by impedance measurements reveals different modes of growth
Hypertrophic growth is a response of the heart to increased mechanical load or physiological stress. Thereby, cardiomyocytes grow… 
2015
2015
Role of phosphoinositide 3-kinase IA (PI3K-IA) activation in cardioprotection induced by ouabain preconditioning.
2015
2015
Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
Gastric cancer is one of the most virulent malignant diseases and is the second leading cause of cancer mortality in the world… 
2013
2013
Molecular and Cellular Pathobiology FOXO 3 a Is a Major Target of Inactivation by PI 3 K / AKT Signaling in Aggressive Neuroblastoma
Neuroblastoma is a pediatric tumor of the peripheral sympathetic nervous system with a highly variable prognosis. Activation of… 
2012
2012
A Yeast-Based In Vivo Bioassay to Screen for Class I Phosphatidylinositol 3-Kinase Specific Inhibitors
The phosphatidylinositol 3-kinase (PI3K) pathway couples receptor-mediated signaling to essential cellular functions by… 
2012
2012
Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration.
2011
2011
Obesity, insulin and chemoresistance in colon cancer.
Obesity, a condition characterised by chronic hyperinsulinemia, is a firmly established risk factor for incident colon cancer (1… 
Highly Cited
2009
Highly Cited
2009
Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Phosphatidylinositol 3-kinase (PI3K) has been implicated in a variety of diseases including cancer. A number of PI3K inhibitors… 
Highly Cited
2008
Highly Cited
2008
Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.
Highly Cited
2008
Highly Cited
2008
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
Rapamycin (or sirolimus), the prototypical inhibitor of the mammalian target of rapamycin (mTOR) and an immunosuppressant used… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)